XML 36 R25.htm IDEA: XBRL DOCUMENT v3.23.1
Segment and Geographic Information (Tables)
 3 Months Ended
Apr. 02, 2023
Industry And Geographic Information [Abstract]  
Revenue from External Customers by Geographic Areas
Total revenues by reportable segment are as follows:
Three Months Ended
(In millions)April 2, 2023April 3, 2022
North America$582.8 $961.5 
EMEA81.3 15.2 
China70.6 8.7 
Other111.4 16.9 
Total revenues$846.1 $1,002.3 
Schedule of Segment Reporting Information, by Segment
The following table sets forth Adjusted EBITDA by segment and the reconciliations to Income before provision for income taxes for the three months ended April 2, 2023 and April 3, 2022:
Three Months Ended
(In millions)April 2, 2023April 3, 2022
North America$278.4 $713.4 
EMEA7.2 3.5 
China28.5 3.8 
Other21.8 9.5 
Total segment Adjusted EBITDA335.9 730.2 
Corporate (1)
(90.6)(89.3)
Depreciation and amortization(114.2)(15.3)
Acquisition and integration costs(29.7)(3.0)
Interest expense, net(36.7)(1.0)
Amortization of deferred cloud computing implementation costs(1.6)(1.0)
Employee compensation charges and other costs(1.5)— 
Impairment of long-lived assets(0.5)— 
EU medical device regulation transition costs (2)
(0.8)— 
Tax indemnification expense(0.3)— 
Income before provision for income taxes$60.0 $620.6 
(1) Primarily consists of costs related to executive and staff functions, including certain finance, human resources, manufacturing and information technology (“IT”) functions, which benefit the Company as a whole. These costs are primarily related to the general management of these functions on a corporate level and the design and development of programs, policies and procedures that are then implemented in the individual segments, with each segment bearing its own cost of implementation. The Company’s corporate function also includes debt and stock-based compensation associated with all employee stock-based awards.
(2) Represents incremental consulting costs and research and development (“R&D”) manufacturing site costs to align compliance of Ortho’s existing, on-market products that were previously registered under the European In Vitro Diagnostics Directive regulatory framework with the requirements under the EU’s In Vitro Diagnostic Regulation, which generally apply from May 2022 onwards.